+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route of Administration, End User, Patient Age Group - Global Forecast to 2030- Product Image
Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route of Administration, End User, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route of Administration, End User, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716358
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Obsessive-Compulsive Disorder Drugs Market grew from USD 969.71 million in 2024 to USD 1.05 billion in 2025. It is expected to continue growing at a CAGR of 8.67%, reaching USD 1.59 billion by 2030.

Unveiling the Strategic Landscape of OCD Drug Development

Obsessive-compulsive disorder affects millions worldwide, yet the therapeutic landscape has only recently seen a surge in innovation and differentiation. As treatment paradigms evolve from one-size-fits-all regimens toward more nuanced pharmacological approaches, understanding the competitive dynamics has never been more critical. This executive summary synthesizes the key trends, market shifts, segmentation insights, and regional dynamics shaping the OCD drugs sector today.

By examining the forces behind drug class performance, distribution strategies, and patient demographics, this report provides a panoramic view of where the market stands and where it is headed. Stakeholders across the value chain-from research scientists and clinical leaders to commercial strategists and payers-will find clarity on how to navigate the complexities of regulatory frameworks, pricing pressures, and evolving patient needs. With this introduction, we set the stage for a comprehensive analysis that informs confident decision-making and fosters long-term growth.

Emergence of Personalized Therapies and Regulatory Evolution

The past five years have borne witness to transformative shifts that are redefining the obsessive-compulsive disorder drugs landscape. Advances in pharmacogenomics have enabled more precise targeting of serotonin and norepinephrine pathways, driving the development of new selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors with improved tolerability profiles. At the same time, investment in next-generation formulations and delivery mechanisms-from extended-release oral tablets to innovative parenteral options-has accelerated, expanding the range of therapeutic choices available to clinicians.

Simultaneously, regulatory agencies have streamlined pathways for medications demonstrating significant clinical benefit, encouraging companies to pursue faster approvals and global launches. The integration of real-world evidence into label expansions and post-marketing commitments is reshaping the clinical evidence base, while digital health tools are enabling remote monitoring of treatment adherence and symptom fluctuations. As a result, the competitive landscape is becoming more dynamic, with a growing emphasis on differentiated clinical data, patient-centric access programs, and strategic licensing partnerships.

Navigating Tariff-Induced Price and Supply Chain Pressures

In 2025, new tariffs imposed by the United States on imported active pharmaceutical ingredients and finished formulations introduced significant cost pressures across the OCD drugs supply chain. Manufacturers reliant on overseas sourcing faced increased production expenses, prompting a reevaluation of procurement strategies and supplier contracts. These tariffs affected not only the core ingredients for SSRIs and SNRIs but also the specialized components required for advanced oral controlled-release systems.

The cumulative impact manifested in a dual challenge: higher wholesale prices for distributors and tighter margins for pharmaceutical companies. In response, many firms accelerated investments in domestic manufacturing capabilities and forged strategic alliances with local contract development and manufacturing organizations. Simultaneously, supply chain resilience became a top executive priority, with contingency planning now incorporating tariff scenarios and reshoring analyses. While short-term inflationary pressures persisted, the industry’s proactive measures are laying the groundwork for a more robust, domestically centered production ecosystem.

Revealing Distinct Market Profiles Across Multiple Segmentation Axes

A comprehensive segmentation analysis reveals distinct patterns across multiple dimensions of the OCD drugs market. Examining the market by drug class uncovers the sustained dominance of SSRIs, driven by established molecules such as citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, while SNRIs-led by desvenlafaxine, duloxetine, and venlafaxine-are gaining ground through differentiated efficacy for comorbid conditions. In contrast, MAOIs like phenelzine and tranylcypromine occupy a niche yet clinically important role for treatment-resistant patients. Tricyclic antidepressants including amitriptyline, clomipramine, and imipramine remain relevant due to their cost-effectiveness and well-characterized safety profiles.

Distribution channel analysis highlights that hospital pharmacies continue to drive patient access within inpatient and acute care settings, whereas online pharmacies are rapidly emerging as a preferred source for chronic therapy refills, fostering convenience and broader geographic reach. Traditional retail pharmacies maintain strong ties with community physicians and serve as critical touchpoints for patient education. When dissecting drug type, branded products command premium pricing and garner loyalty through innovation and support programs, while generic alternatives fuel volume uptake and cost containment efforts.

Route of administration underscores that oral formulations represent the vast majority of prescriptions, yet parenteral options are rising in prominence for treatment-refractory cases and rapid symptom management. End user segmentation demonstrates that hospitals and clinics account for the majority of initial prescribing and dose adjustments, whereas households represent the largest share of ongoing therapy adherence. Finally, patient age group analysis differentiates the adult population as the primary consumer of OCD medications, even as pediatric formulations and tailored dosing regimens gain traction to address early-onset presentations.

Contrasting Regional Dynamics That Shape Market Access

Regional dynamics further shape the OCD drugs market, with the Americas maintaining leadership fueled by a high prevalence of diagnosis, robust reimbursement frameworks, and a concentration of major pharmaceutical headquarters. In this region, payer-driven formularies and patient assistance initiatives play a critical role in determining product uptake and lifecycle management strategies.

In Europe, Middle East & Africa, heterogeneous regulatory landscapes and varying healthcare infrastructure levels present both challenges and opportunities. Established markets in Western Europe showcase rapid adoption of innovative therapies, whereas emerging markets in the Middle East and Africa are exhibiting gradual growth as diagnostic awareness and treatment accessibility improve. Collaborative programs between public health agencies and private sector entities are essential to bridge gaps in care and foster equitable access.

Asia-Pacific stands out for its high population density, rising mental health awareness, and expanding pharmaceutical manufacturing base. Countries such as Japan and Australia are early adopters of novel OCD treatments, while emerging economies in Southeast Asia and South Asia are witnessing accelerating pharmacy retail expansion and online distribution models. Strategic partnerships between global companies and regional distributors are crucial for navigating local regulatory nuances and optimizing market entry.

Strategic Maneuvers Defining the Competitive Battlefield

The competitive landscape of OCD therapeutics features a mix of established multinational pharmaceutical corporations and agile specialty biotechs. Leading companies have fortified their market positions through strategic product launches, high-impact clinical trials, and diversified pipelines spanning next-generation SSRIs, SNRIs, and novel mechanism agents. Some market leaders have pursued bolt-on acquisitions to augment their portfolios with complementary therapies and in-house manufacturing capabilities, while others have prioritized licensing deals to secure regional commercialization rights in high-growth territories.

Emerging players are differentiating themselves by focusing on rare patient subsets, leveraging orphan drug designations, and investing in real-world evidence generation to demonstrate superior outcomes. Collaborative research agreements with academic institutions and technology firms are fostering innovation in drug delivery and digital adherence tools. In parallel, companies are optimizing their commercial models by integrating value-based contracting and outcome-linked pricing, aligning reimbursement with demonstrated clinical benefit.

Prioritizing Resilience, Data, and Collaborative Innovation

Industry leaders should prioritize diversification of manufacturing footprints to mitigate geopolitical and tariff-related risks. By establishing localized production in key markets, they can protect margins and ensure uninterrupted supply. Furthermore, investing in advanced data analytics and real-world evidence platforms will enable more precise targeting of patient segments and support product differentiation in crowded therapeutic classes.

Collaboration with regulatory bodies to streamline approval pathways and expand labeling based on real-world outcomes can accelerate time to market. Equally important is forging partnerships with digital health providers to integrate telemedicine and remote monitoring into comprehensive care solutions, enhancing adherence and enabling personalized dosing adjustments. Finally, adopting value-based contracting frameworks will foster stronger payer relationships and demonstrate a commitment to delivering measurable improvements in patient quality of life.

Underpinning Insights with a Robust Multisource Methodology

This analysis is grounded in a rigorous research methodology that blends extensive primary and secondary data sources. Primary research includes in-depth interviews with industry executives, clinical experts, regulatory officials, and distribution channel stakeholders. These conversations provide firsthand insights into competitive strategies, patient access challenges, and evolving prescribing behaviors.

Secondary research comprises a systematic review of peer-reviewed journals, regulatory filings, company financial reports, and market intelligence databases. All data points are triangulated to validate accuracy and consistency. Quantitative findings are cross-verified through multiple independent sources, while qualitative trends are evaluated for alignment with observed industry dynamics. Throughout the process, methodological rigor is upheld by adherence to standardized research protocols and continuous peer review to minimize bias.

Synthesizing Insights to Illuminate Strategic Pathways

The obsessive-compulsive disorder drugs market stands at a pivotal juncture, shaped by technological advances, evolving patient needs, and shifting economic conditions. Emerging therapies and delivery platforms promise to redefine treatment paradigms, while tariff-driven supply chain recalibrations underscore the need for strategic agility. Segmentation and regional analyses reveal multifaceted market profiles, guiding stakeholders toward tailored commercialization approaches.

As competitive intensity intensifies, organizations that embrace data-driven decision-making, foster collaborative innovation, and adapt to dynamic regulatory environments will secure leadership positions. The insights presented herein offer a clear roadmap for navigating the complexities of the OCD therapeutics landscape and capitalizing on opportunities to enhance patient outcomes and drive sustainable growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • MAOIs
      • Phenelzine
      • Tranylcypromine
    • SNRIs
      • Desvenlafaxine
      • Duloxetine
      • Venlafaxine
    • SSRIs
      • Citalopram
      • Fluoxetine
      • Fluvoxamine
      • Paroxetine
      • Sertraline
    • TCAs
      • Amitriptyline
      • Clomipramine
      • Imipramine
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Drug Type
    • Brand
    • Generic
  • Route Of Administration
    • Oral
    • Parenteral
  • End User
    • Clinics
    • Hospitals
    • Households
  • Patient Age Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class
8.1. Introduction
8.2. MAOIs
8.2.1. Phenelzine
8.2.2. Tranylcypromine
8.3. SNRIs
8.3.1. Desvenlafaxine
8.3.2. Duloxetine
8.3.3. Venlafaxine
8.4. SSRIs
8.4.1. Citalopram
8.4.2. Fluoxetine
8.4.3. Fluvoxamine
8.4.4. Paroxetine
8.4.5. Sertraline
8.5. TCAs
8.5.1. Amitriptyline
8.5.2. Clomipramine
8.5.3. Imipramine
9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type
10.1. Introduction
10.2. Brand
10.3. Generic
11. Obsessive-Compulsive Disorder Drugs Market, by Route of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
12. Obsessive-Compulsive Disorder Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Households
13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Obsessive-Compulsive Disorder Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Obsessive-Compulsive Disorder Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Obsessive-Compulsive Disorder Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Eli Lilly and Company
17.3.3. GlaxoSmithKline plc
17.3.4. H. Lundbeck a/S
17.3.5. Teva Pharmaceutical Industries Ltd.
17.3.6. Novartis AG
17.3.7. Sun Pharmaceutical Industries Ltd.
17.3.8. Viatris Inc.
17.3.9. Otsuka Pharmaceutical Co., Ltd.
17.3.10. Johnson & Johnson
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 69. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 70. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 71. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 72. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 130. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 140. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 160. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 161. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 162. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 163. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ITALY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SPAIN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 210. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 215. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. DENMARK OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 230. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 231. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 232. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 233. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. QATAR OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 240. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 245. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. FINLAND OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 270. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 275. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. EGYPT OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 278. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 280. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 285. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. TURKEY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 298. NORWAY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. NORWAY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2030 (USD MILLION)
TABLE 300. NORWAY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Obsessive-Compulsive Disorder Drugs market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.05 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.59 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Obsessive-Compulsive Disorder Market Report 2025 - Product Image

Obsessive-Compulsive Disorder Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Obsessive-Compulsive Disorder Drugs Market by Sub-Type, by Drugs, by Route of Administration, by Population Type, by End-user, and by Region - Product Image

Obsessive-Compulsive Disorder Drugs Market by Sub-Type, by Drugs, by Route of Administration, by Population Type, by End-user, and by Region

  • Report
  • 200 Pages
  • Global
From
Obsessive-Compulsive Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Obsessive-Compulsive Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Obsessive Compulsive Disorder- Pipeline Insight, 2025 - Product Image

Obsessive Compulsive Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Obsessive-compulsive Disorder Drugs Market 2025-2029 - Product Image

Obsessive-compulsive Disorder Drugs Market 2025-2029

  • Report
  • 217 Pages
  • Global
From

About the Obsessive Compulsive Disorder Drug Market

Obsessive Compulsive Disorder (OCD) is a mental disorder characterized by intrusive thoughts that produce anxiety, and by repetitive behaviors aimed at reducing that anxiety. OCD is treated with a combination of psychotherapy and medication. Drugs used to treat OCD include selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors (MAOIs). SSRIs are the most commonly prescribed medications for OCD, as they are generally well-tolerated and have fewer side effects than other medications. The OCD drug market is highly competitive, with a number of major pharmaceutical companies offering products. These include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Other companies, such as Lundbeck, Otsuka, and Sunovion, also offer products for the treatment of OCD. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.